For a patient taking ticagrelor (Brilinta) who requires excision of a thumb ganglion cyst, how many days should ticagrelor be discontinued before the procedure, and can aspirin be continued?

Ticagrelor Management for Thumb Ganglion Cyst Excision

For a minor procedure like thumb ganglion cyst excision, discontinue ticagrelor 5 days before surgery and continue aspirin throughout the perioperative period.

Rationale for This Recommendation

The 2018 Canadian Cardiovascular Society guidelines provide the clearest framework for this scenario. For elective noncardiac surgery in patients on dual antiplatelet therapy (DAPT), ticagrelor should be withheld for 5-7 days preoperatively 1. The FDA label for Brilinta (ticagrelor) specifically states: "When possible, interrupt therapy with BRILINTA for five days prior to surgery that has a major risk of bleeding" 2.

Why 5 Days?

• Ticagrelor has a reversible binding mechanism to the P2Y12 receptor, but adequate platelet function recovery requires approximately 5 days in most patients 1
• While some cardiac surgery data suggest 3-day discontinuation may be acceptable in urgent situations 3, 4, this carries significant interindividual variability - approximately 25% of patients still have inadequate platelet recovery at 72 hours 3, 5
• The French Working Group on Perioperative Haemostasis recommends 5 days for standard procedures, extending to 7 days for intracranial neurosurgery 3

Aspirin Management

Continue aspirin perioperatively for this minor procedure. The guidelines consistently recommend continuing aspirin whenever possible during noncardiac surgery 1. Key evidence:

• The 2018 CCS guidelines state: "we suggest continuing ASA perioperatively whenever possible" (Weak Recommendation; Low-Quality Evidence) 1
• Ganglion cyst excision is a low bleeding-risk procedure - the practical tip in the guidelines specifically notes that "some minor surgical procedures carry a low risk of bleeding...and can be performed without stopping antiplatelet therapy" 1
• The 2022 CHEST guidelines support perioperative aspirin continuation in most noncardiac surgeries 6

Practical Implementation

Preoperative Timeline:

• Day -5: Last dose of ticagrelor (90 mg)
• Days -4 to 0: Continue aspirin 75-100 mg daily
• Day 0: Proceed with surgery while on aspirin monotherapy

Postoperative Management:

• Resume ticagrelor as soon as hemostasis is achieved - typically within 24-48 hours for this minor procedure 1
• Continue aspirin throughout
• The FDA label emphasizes: "restart it as soon as possible" after temporary discontinuation 2

Critical Caveats

Thrombotic Risk Assessment:

You must balance bleeding versus thrombotic risk. If the patient had recent PCI (percutaneous coronary intervention):

• Surgery should ideally be delayed at least 3 months after drug-eluting stent (DES) placement 1
• If surgery cannot be delayed and patient is within 3 months of DES, strongly consider proceeding with continued DAPT given the catastrophic consequences of stent thrombosis versus manageable bleeding from a thumb procedure

When to Deviate from 5-Day Rule:

• Urgent/emergent surgery: Minimum 48-72 hours may be acceptable if surgery cannot wait 1
• Very high bleeding-risk procedures (e.g., intracranial): Consider 7-day discontinuation 3
• Patient on ticagrelor for recent stroke/TIA: Weigh stroke recurrence risk more heavily

Coordination is Essential:

The guidelines emphasize that "antiplatelet therapy management in the perioperative period should be based on a balanced assessment of the risks of coronary thrombotic complications vs the risk of perioperative bleeding in discussion with the surgeon, interventional cardiologist, attending physician/cardiologist, and the patient" 1.

Common Pitfalls to Avoid

1. Don't stop aspirin for this low-risk procedure - the thrombotic risk outweighs minimal bleeding risk
2. Don't delay ticagrelor resumption unnecessarily - early resumption (within 24-48 hours) is safe for minor procedures and reduces thrombotic risk
3. Don't use platelet function testing routinely - while some data suggest utility in cardiac surgery 3, it's not recommended for routine noncardiac procedures and adds unnecessary complexity
4. Don't forget to verify the indication - if patient is on ticagrelor for recent ACS or within 12 months of stent placement, thrombotic risk is substantially higher

The 5-day discontinuation with aspirin continuation represents the optimal balance of safety and efficacy for this clinical scenario 1, 2.